Mike Thompson – Chief Executive, ABPI, UK
Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry (ABPI) reveals his staunch faith in the British health service but calls for the NHS to welcome and…
Address: Janssen, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, United Kingdom
Tel: +44 (0) 1494 567567
Web: http://www.janssen.co.uk/
In 1947, Ortho Pharmaceuticals was brought into the Johnson & Johnson group of companies and set up a UK base in Lane End, Buckinghamshire.
Johnson & Johnson’s pharmaceutical interests expanded over the next decades with the addition of the Swiss company Cilag Chemie in 1959 and the Belgian company Janssen Pharmaceutica in 1961. Both of these companies had grown from small research laboratories into successful multinationals.
Ortho moved to a site in Saunderton, Buckinghamshire in the early 1950s. Janssen established its first British offices in Marlow, Buckinghamshire, in 1974 and moved to Grove in Oxfordshire a decade later.
Ortho became Ortho Cilag in 1982 and then Cilag in 1988. On 1st January 1995, Cilag and Janssen merged to become Janssen-Cilag Ltd and all operations were transferred to the Saunderton site. In May 2008, the company moved to new offices in High Wycombe.
In September 2000, Ortho Biotech was established, a company specialising in treatments for conditions such as renal disease and cancer.
Tibotec was established in 1994 as a drug discovery laboratory, it evolved to a fully integrated pharmaceutical company focussing on the discovery and the development of new drugs for infectious diseases. In April 2002, Tibotec was acquired by Johnson & Johnson and became a division of Janssen-Cilag.
In 2010, Janssen-Cilag became Janssen and now employs more than 400 people. Its head office is in High Wycombe, Buckinghamshire and also has an office in Dublin.
Janssen is one of the world’s leading research-based pharmaceutical companies, with operations throughout the world. In the UK, Janssen employs more than 400 people.
The company is committed to delivering great medicines and has introduced a range of innovative treatments that can make an important difference to the lives of patients with serious health conditions such as schizophrenia, epilepsy, multiple myeloma and HIV/AIDS. Janssen has one of the strongest development pipelines in the industry with research now focusing on five key areas. These key areas are: neuroscience, oncology, immunology, metabolism and infectious diseases.
Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry (ABPI) reveals his staunch faith in the British health service but calls for the NHS to welcome and…
Liam O’Toole, CEO of Arthritis Research UK, discusses how arthritis impacts the British economy, raising public awareness of the condition, the potential ramifications of Brexit, and the importance of inter-stakeholder…
Mark Hicken, managing director of the UK and Ireland operations of Janssen, the pharmaceutical arm of Johnson & Johnson, highlights the company’s long-standing R&D presence in the UK. He calls…
Sir Robert Lechler, president of the Academy of Medical Sciences (AMS), discusses the Academy’s role in promoting medical research in the UK and how that stands to change in the…
Keith Thompson, CEO of the Cell & Gene Therapy Catapult, one of a number of Catapult institutions in the UK designed to help commercialize innovative research, discusses strategy, funding, international…
Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues, and why Biogen is staying the course with…
Sir John Savill, chief executive of the Medical Research Council between 2010 and 2018, discusses the organization’s transition into part of the new UK Research and Innovation (UKRI) grouping, the…
Steve Ford, CEO of Parkinson’s UK, one of the UK’s leading research-based charities, discusses his organization’s recent Digital Leadership Award, presenting the needs of Parkinson’s patients to stakeholders, and why…
Tony Jones, CEO of One Nucleus, a life sciences membership organization centered on the Greater London-Cambridge-East of England corridor, discusses the role of SMEs within the UK’s healthcare ecosystem, translational…
Lord O’Shaughnessy, parliamentary under secretary of state for health in the UK, discusses how stakeholders are interacting to ensure that the UK remains at the forefront of the global life…
Ben Ellis, general manager at Lupin UK and Ireland, talks about the strategic challenges of transitioning from the sphere of generics to specialist pharma and how he hopes Lupin can…
Sir John Chisholm, executive chair of Genomics England – a company set up and owned by the UK Department of Health to run the 100,000 Genomes Project, which aims to…
See our Cookie Privacy Policy Here
